高级别唾液腺癌中PD-L1表达的发生率及预后意义

Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.

作者信息

Fang Qigen, Wu Yao, Du Wei, Zhang Xu, Chen Defeng

机构信息

Department of Head Neck and Thyroid, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Front Oncol. 2021 Aug 26;11:701181. doi: 10.3389/fonc.2021.701181. eCollection 2021.

OBJECTIVE

PD-L1 is one of the predictors of immunotherapy efficacy. Our goal was to analyze its expression and prognostic significance in high-grade salivary gland carcinoma (SGC).

METHODS

PD-L1 expression was evaluated using paraffin-embedded specimens from patients with surgically treated high-grade SGC, and it was scored by the tumor proportion score (TPS), combined positive score (CPS), and immune cell (IC) score. Associations between clinicopathological variables, disease-free survival (DFS), overall survival (OS) and PD-L1 expression were assessed.

RESULTS

TPS≥1% occurred in 47 patients with an incidence of 43.1%, and it was significantly related to an advanced tumor stage. In patients with TPS<1%, TPS ranging from 1% to 20%, and TPS≥20%, the 5-year DFS rates were 36%, 26%, and 13%, respectively, and the difference was significant. In patients with TPS<1%, TPS ranging from 1% to 20%, and TPS≥20%, the 5-year OS rates were 49%, 24%, and 13%, respectively, and the difference was significant. CPS≥1 occurred in 87 patients with an incidence of 79.8%. IC scores of 0, 1, 2, and 3 were noted in 24 (22.0%), 37 (33.9%), 31 (28.4%), and 17 (15.6%) patients, respectively. Both CPS and IC scores had no impact on DFS or OS.

CONCLUSIONS

The expression of PD-L1 in tumor cells of high-grade SGCs was not uncommon, and it was significantly associated with tumor stage. PD-L1 expression in tumor cells rather than in immune cells indicated a poor prognosis.

目的

程序性死亡受体配体1（PD-L1）是免疫治疗疗效的预测指标之一。我们的目标是分析其在高级别涎腺癌（SGC）中的表达及预后意义。

方法

使用手术治疗的高级别SGC患者的石蜡包埋标本评估PD-L1表达，并通过肿瘤比例评分（TPS）、联合阳性评分（CPS）和免疫细胞（IC）评分进行评分。评估临床病理变量、无病生存期（DFS）、总生存期（OS）与PD-L1表达之间的关联。

结果

47例患者TPS≥1%，发生率为43.1%，且与肿瘤晚期显著相关。TPS<1%、TPS为1%至20%以及TPS≥20%的患者，5年DFS率分别为36%、26%和13%，差异有统计学意义。TPS<1%、TPS为1%至20%以及TPS≥20%的患者，5年OS率分别为49%、24%和13%，差异有统计学意义。87例患者CPS≥1，发生率为79.8%。24例（22.0%）、37例（33.9%）、31例（28.4%）和17例（15.6%）患者的IC评分为0、1、2和3。CPS和IC评分均对DFS或OS无影响。